Objective To explore the effect of sacubitril and valsartan in the treatment of heart failure with preservation of ejection fraction. Methods?80 patients with heart failure with preserved ejection fraction admitted from June 2019 to July 2020 were selected as the research subjects，and were grouped by random number table. 40 patients in the control group received standardized anti-heart failure treatment，and 40 patients in the observation group changed the control group benazepril to sacubitril and valsartan. Compare the treatment effects of the two groups. Results?The total effective rate of treatment in the observation group was 95.00%，which was significantly higher than 77.50% in thecontrol group，and the rehospitalization rate was lower than that in the control group（P ＜ 0.05）；After treatment，the observation group had significant differences in troponin I（cTn Ⅰ），plasma N-terminal pro-B-type natriuretic peptide（NT-pro BNP）compared with the control group（P ＜ 0.05）；after intervention in the observation group，left ventricular ejection fraction（LVEF），left ventricular end diastolic diameter（LVEDD），peak E peak A ratio of mitral valve（E/A），left ventricular short axis shortening rate（FS），left atrial diameter（LA）compared with the control group，there was no significant difference（P ＞ 0.05）. Conclusion?The use of sacubitril and valsartan in the treatment of heart failure with preservation of ejection fraction can improve the symptoms of patients and reduce the rate of rehospitalization，but it has no obvious effect on improving cardiac remodeling in the short term，so long-term observation of its efficacy is required.